Bristol-Myers Squibb BuSpar
Executive Summary
FDA grants pediatric marketing exclusivity extension to BuSpar (buspirone) until Nov. 22. Exclusivity for the anxiety disorder treatment would have expired May 22. FDA issued a second tentative approval May 23 to four companies for generic versions of buspirone. BuSpar had sales of $568 mil. in 1999